Atrazine (ATR) is a commonly used pre-emergence/early postemergence herbicide. Previous work has shown that exposure to high doses of ATR in rats results in blunting of the hormone-induced luteinizing hormone (LH) surge and inhibition of pulsatile LH release without significantly reducing pituitary sensitivity to a gonadotropin-releasing hormone (GnRH) agonist. Accompanying the reduction in the LH surge was an attenuation of GnRH neuronal activation. These findings suggest that ATR exposure may be acting to inhibit GnRH release. In this study, we examined GnRH directly to determine the effect of high doses of ATR on GnRH pulsatile release, gene expression, and peptide levels in the female rat. Ovariectomized adult female Wistar rats were treated with ATR (200 mg/kg) or vehicle for 4 days via gavage. Following the final treatment, GnRH release was measured from ex vivo hypothalamic explants for 3 h. In another experiment, animals were administered either vehicle or ATR (50, 100, or 200 mg/kg) daily for 4 days. Following treatment, in situ hybridization was performed to examine total GnRH mRNA and the primary GnRH heterogeneous nuclear RNA transcript. Finally, GnRH immunoreactivity and total peptide levels were measured in hypothalamic tissue of treated animals. ATR treatment resulted in no changes to GnRH gene expression, peptide levels, or immunoreactivity but a reduction in GnRH pulse frequency and an increased pulse amplitude. These findings suggest that ATR acts to inhibit the secretory dynamics of GnRH pulses without interfering with GnRH mRNA and protein synthesis. endocrine disruptors, gonadotropin-releasing hormone (GnRH/ GnRH receptor)
INTRODUCTION
Atrazine (ATR) is a pre-emergence/early postemergence herbicide commonly used in corn, sorghum, and sugar cane fields. When administered to rats, ATR has been shown to exert effects on several reproductive and endocrine parameters. In female rats, ATR has been shown to inhibit both the luteinizing hormone (LH) surge and pulsatile release [1] [2] [3] . ATR can also prolong the estrous cycle [4, 5] , delay the onset of puberty in both sexes [6, 7] , and induce characteristics of premature reproductive aging in female Sprague-Dawley rats [8, 9] .
The results of all these studies have lead to the hypothesis that ATR's impact on reproduction is attributable to an alteration in gonadotropin-releasing hormone (GnRH) signaling to the pituitary, resulting in disrupted downstream LH secretion and all the subsequent ramifications of such inhibition. The secretion of GnRH into the hypophyseal portal blood is the final common pathway responsible for the neuroendocrine control of reproduction. The episodic pattern of release of GnRH and the corresponding release of LH from the anterior pituitary gland are required for normal reproductive function (for reviews, see [10, 11] ). Disruption of GnRH/LH pulsatility leads to a reduction in gonadotropin secretion and loss of reproductive function [12] [13] [14] . We have previously shown that ATR blunts the LH surge without reducing pituitary sensitivity to a GnRH agonist and reduces the degree of GnRH neuron activation [2, 3] . In addition, we have shown that ATR treatment results in a reduction in LH pulse frequency and an increase in pulse amplitude [2] . Given the close association between GnRH and LH release patterns and evidence of no change in pituitary sensitivity, these findings suggest that the effect of ATR on LH may be through a reduction in GnRH release. In the present study, we tested this hypothesis by measuring GnRH release ex vivo from hypothalamic explants of ATR-and vehicle-treated (control) animals. We also evaluated the potential effect of ATR on the expression of GnRH mRNA, its primary transcript, and peptide levels.
MATERIALS AND METHODS

Animals
All animal surgeries and experimental protocols were approved by the Animal Care and Use Committee of Auburn University or Arizona State University under subcontract with the University of Arizona College of Medicine-Phoenix and were carried out in accordance with National Institutes of Health and Association for Assessment and Accreditation of Laboratory Animal Care guidelines. Young adult female Wistar rats (age, 60-90 days) were obtained from Charles River Laboratories. Animals were double-housed in the Auburn University or Arizona State University vivarium and maintained on a 10D:14L photoperiod (lights-on, 0700 h) with ad libitum access to food and water. Following at least 4 days to acclimate to the vivarium, all animals were ovariectomized and allowed 7-10 days to recover before additional procedures.
approximately 0900 h for 4 days. This dose of ATR has previously been shown to inhibit pulsatile LH release in vivo [2] . Approximately 30 min after administration of the final gavage dose on the fourth day of treatment, animals were anesthetized with isoflurane and decapitated. The brain was quickly removed from the skull and bisected with a sagittal cut through the midline. The hypothalamus was dissected out by making a lateral cut at the hypothalamic fissures, an anterior cut 2 mm rostral to the optic chiasm, a posterior cut at the rostral domain of the mammillary bodies, and a horizontal cut at the hypothalamic sulcus. Hemihypothalamic sections were immediately placed in chilled, sterile artificial cerebrospinal fluid (aCSF; 140 mM NaCl, 3.35 mM KCl, 1.15 mM MgCl 2 , 1.26 mM CaCl 2 , 1.2 mM Na 2 HPO 4 , and 0.3 mM NaH 2 PO 4 ; pH 7.4). All tissue perifusion experiments were performed using an Acusyst S-APS 10 programmable flow-through perifusion system (Endotronics, Inc.). Hypothalamic explants were placed in the perifusion apparatus and superfused with warmed (378C) and oxygenated aCSF at a flow rate of 100 ll/min through chambers containing one hemihypothalamus from each rat. Tissue was allowed to stabilize for 30 min before sample collection commenced. Experiments were conducted for 3 h, with 500 ll of perfusate fractions collected at 5-min intervals. Samples were collected on ice, quickly frozen, and stored at À808C until assayed.
At the end of the perifusion period, all tissues were exposed to a bolus of KCl (50 mM) in aCSF to verify that tissue secretory properties had not been disrupted and tissue remained viable. KCl exposure lasted for 10 min, and samples were taken for an additional 20 min. Tissue was considered to be responsive to KCl stimulation if GnRH levels reached twofold the coefficient of variation of the assay at the mean level. All unresponsive explants were removed from analysis, leaving eight animals per treatment group.
Experiment 2: Effects of ATR on GnRH mRNA Expression
To determine if ATR treatment results in a change in GnRH gene expression, in situ hybridization (ISH) was performed on brain sections from ATR-and vehicle-treated animals. Ovariectomized rats were gavaged daily for 4 days with vehicle (1% CBC) or one of three doses of ATR (50, 100, or 200 mg/kg). These doses have previously been shown to inhibit LH pulse and surge release in vivo [2, 3] . Thirty minutes after gavage on the fourth day of treatment, animals were anesthetized with isoflurane and decapitated. Brains were removed and quickly frozen in 2-methylbutane (À148C) and stored at À708C until sectioning. Using a Leica CM3050S cryostat, brains were sectioned (section thickness, 16 lm), placed on Superfrost Plus slides (VWR Scientific), and stored at À708C until further processing for ISH as previously described [15] . Briefly, every 10th tissue section from the preoptic area (POA) through the mediobasal hypothalamus (MBH) from each animal was thawed at room temperature, fixed with 4% formaldehyde, acetylated with 0.25% acetic anhydride, delipidated in chloroform, dehydrated in graded alcohols, and airdried. A 48-base oligonucleotide probe complementary to the coding region of GnRH mRNA (5 0 TTC AGT ATT TCT CTT CCC CCC AGG GCG CAA CCC ATA GGA CCA GTG CTG 3 0 ) was 3 0 end-labeled with [ 35 S]dATP using terminal deoxynucleotide transferase (Promega). Specific activity of the labeled probe was approximately 2 3 10 7 cpm/pmol. Sections were hybridized with labeled probe (1.5 3 10 7 cpm/ml) in hybridization buffer (0.6 M NaCl, 10 mM Tris, 13 Denhart, 1 mM ethylenediaminetetra-acetic acid, 10% dextran sulfate, 50% formamide, 0.1 mg/ml of salmon sperm DNA, 0.5 mg/ml of total yeast RNA, 0.05 mg/ml of yeast tRNA, and 0.1% sodium dodecyl sulfate) for 16 h at 408C in a humidified incubator. Sections were then washed in 23 standard saline citrate (SSC) to remove unbound probe, and nonspecific hybridization was removed by a series of washes of increasing stringency, with final stringency at 23 SSC and 458C with 50% formamide. Slides were air-dried, dipped in Kodak NTB-3 nuclear tract emulsion, and allowed to expose for 15 days at 48C. Following developing, slides were counterstained with cresyl violet.
To determine the level of primary transcript for GnRH, alternate sections from the brain of the same animals described above were used. A protocol similar to that described above was performed using a probe specific for intron B of the primary GnRH RNA (generously provided by Sandy Petersen, University of Massachusetts, Amherst). The 330-bp fragment was transcribed with T7 polymerase in the presence of [ 35 
S]UTP and [
35 S]CTP, transcription buffer, 10 mM dithiothreitol, 20 U of RNAsin, 1 mM GTP, and 10 U of RNA polymerase, then incubated for 30 min at 378C. After incubation, the reaction mixture was brought to 100 ll with nuclease-free H 2 O, and the template was degraded with 1 U of DNase I (Promega) in the presence of 10 U of RNAsin (Promega). Probes were then ethanol precipitated to remove unincorporated nucleotides. A small fraction of the final probe was run on an agarose gel to reveal a single product at the appropriate size. Hybridization buffer with labeled probe was placed on slides and incubated overnight at 608C. Slides were then dipped in Kodak NTB-3 emulsion, dried, and exposed in the dark for 21 days. The emulsion was developed in Dektol (Kodak). The sections were counterstained with cresyl violet, dehydrated, and cover-slipped with DPX (EM Sciences).
Experiment 3: Effects of ATR on GnRH Immunoreactivity and Peptide Levels
Ovariectomized rats were administered ATR (200 mg/kg) or vehicle (1% CBC) via gavage (;500 ll) once daily at approximately 0900 h for 4 days. This dose of ATR has previously been shown to inhibit pulsatile LH release in vivo [2] . Approximately 30 min after the administration of the final gavage dose on the fourth day of treatment, animals were anesthetized with isoflurane and decapitated. The brain was quickly removed from the skull and bisected with a sagittal cut through the midline. The hypothalamus was dissected out by making an anterior cut 2 mm rostral to the optic chiasm, a posterior cut at the rostral domain of the mammillary bodies, and a horizontal cut at the hypothalamic sulcus. Tissue was fast-frozen in liquid nitrogen and stored at À708C until processing for radioimmunoassay (RIA).
Another cohort of animals was similarly treated and anesthetized with ketamine and perfused transcardially with 4% paraformaldehyde. After fixation, brains were removed, postfixed in 4% paraformaldehyde overnight, and then placed in 30% sucrose for cryoprotection. After sucrose infiltration, brains were cut on a cryostat (section thickness, 35 lm). Every fourth section was processed for GnRH using immunohistochemistry [15] .
Radioimmunoassay
Perfusate (sample size, 100 ll) levels of GnRH were measured by RIA. Intra-assay coefficient of variation for GnRH was 6.3%, and assay sensitivity was 12 pg/ml. All samples were assayed in triplicate in one assay. Tracer GnRH was iodinated at the Animal Reproduction and Biotechnology Laboratories at Colorado State University. The GnRH antibody used was pool R42 (1:120 000; generously provided by Dr. Terry Nett, Colorado State University, Fort Collins, CO).
Quantification and extraction of brain GnRH peptide was carried out at the Endocrinology Laboratory at the Animal Reproduction and Biotechnology Laboratory at Colorado State University. GnRH levels were measured via RIA. Intra-assay coefficient of variation for GnRH was 8.1%, and assay sensitivity was 24 pg/ml. All samples were assayed in one assay.
Immunohistochemistry
To determine the degree of GnRH immunoreactivity, sections were removed from cryopreservative solution [16] and repeatedly washed in 0.1 M PBS. The procedure was carried out on free-floating sections at room temperature. The sections were incubated in PBSTX (PBS containing 10% normal goat serum [Jackson Laboratories, Inc.] and 0.4% Triton X-100 [Sigma]) for 1 h. Sections were then incubated in PBSTX for 16 h with a rabbit polyclonal antibody against GnRH (1:5000; PA1-120; Pierce Antibodies). Following incubation, sections were washed and then placed in a solution of PBSTX with biotinylated goat anti-rabbit immunoglobulin G (1:1000; Vector Labs) for 1 h. The sections were subsequently washed and incubated for 1 h in avidin-biotin complex (1:1000; Vector Labs). Sections were reacted using unenhanced 3,3 0 -diaminobenzidine as the chromogen. Immunohistochemical controls included omission of one or both of the primary antibodies from the immunostaining protocol, the absence of which completely eliminated staining for the antigen.
Image Analysis
The density of hybridization signal was determined from emulsion-coated slides using a Sony XC-77 camera connected to a Zeiss Axioplan microscope. Images were imported with a QuickCapture framegrabber board (Data Translation, Inc.) and a Dell computer utilizing Scion Image software (Scion Corporation). Sections were atlas matched [17] , and areas were identified by examining cresyl violet-stained tissue under bright-field microscopy. Silver grains were then visualized by dark-field microscopy with a 203 objective. Under dark field, microscopic images encompassing a defined brain region were captured. Images were inverted using Scion Image software, and hybridization density was determined. Microscopic light intensity was held constant in all analyses. GnRH cells were identified and counted from emulsion-coated slides by an experimenter blind to the experimental group and using the following criteria: grain density greater than fivefold background (background determined by counting grains over a cellular area outside POA, anterior hypothalamic area, and MBH), and a visible nucleus identified by cresyl violet staining. An average of five consecutive sections per brain region per animal, separated by 80 lm, were examined. The average number of grains FORADORI ET AL.
per GnRH cell and the total number of identified cells were calculated for each animal.
For immunohistochemistry, the locations of GnRH-immunoreactive (GnRH-ir) cells were examined in a series of every fourth section through the POA and hypothalamus of each animal. For each animal, the total number of GnRH-ir cells was counted on a Nikon E800.
Data Analysis
For GnRH concentration data from experiment 1, pulsatile GnRH secretion was analyzed using a method similar to that described by Gallo [18] . A pulse was defined as a family of points for which the coefficients of variation of the ascending and descending limbs were greater than twofold the coefficient of variation of the assay at the mean level. The pulse amplitude was calculated by subtracting the preceding nadir value from the greatest pulse value. An unpaired t-test was used to determine differences. For GnRH expression levels from experiment 2, an ANOVA was performed on all data. In experiment 3, GnRH peptide levels and the mean number of GnRH-ir cells were compared using an unpaired t-test. Prism 5 for Mac (GraphPad Software, Inc.) was used for all data analysis. Significance was set at P , 0.05.
RESULTS
Experiment 1: Effects of ATR on Ex Vivo Hypothalamic GnRH Release
Hypothalamic explants from ATR (200 mg/kg)-treated animals displayed an altered GnRH release pattern compared to that identified in the control animals ( Fig. 1) . Hypothalamic explants from ATR-treated animals had fewer GnRH pulses during the sampling period than control explants (ATR, 4.2 6 0.36 [mean 6 SEM]; control, 6.0 6 0.39; P , 0.05, t(14) ¼ 3.3) (Fig. 2A) . However, when GnRH pulses occurred in the ATR group, they had higher amplitude than in controls (ATR, 223.7 6 39.9; control, 96.4 6 26.1; P , 0.05, t(14) ¼ 2.7) (Fig. 2B) . No difference was found between the mean area under the curve for the combined GnRH pulses for each animal in the two treatment groups (ATR, 87.2 6 10.1; control, 82.7 
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6 11.2; P ¼ 0.77, t(14) ¼ 0.3) (Fig. 2C) . No difference was found in the peak GnRH levels elicited by KCl exposure due to treatment (data not shown).
Experiment 2: Effects of ATR on GnRH Expression
Using ISH, we found no significant changes in the expression of GnRH mRNA after any dose of ATR. No differences were found in the mean number of cells expressing GnRH mRNA or in GnRH mRNA cellular distribution (F 3,24 ¼ 0.8, P ¼ 0.23) (Fig. 3A) . When analyzed on a cell-by-cell basis, no difference was found in the mean number of silver grains per cell (F 3,24 ¼ 0.66, P ¼ 0.97) (Fig. 3B) .
Similarly, the number of cells identified as expressing GnRH heterogeneous nuclear RNA (hnRNA) was not different between treatment groups (F 3,24 ¼ 0.40, P ¼ 0.75) (Fig. 3C ), nor were differences found in grains per cells associated with ATR treatment (F 3,24 ¼ 0.38, P ¼ 0.76) (Fig. 3D) . GnRH mRNA-and hnRNA-expressing cells were also analyzed in reference to their location in the POA and hypothalamus. No significant differences were found in the expression level (number of cells or grains per cell) of GnRH in the diagonal band of Broca/medial septum, medial POA, anterior/lateral hypothalamus, and the medial basal hypothalamus (data not shown).
Experiment 3: Effects of ATR on GnRH Immunoreactivity and Peptide Levels
Using immunohistochemistry and RIA, we found no significant changes in GnRH peptide levels after ATR treatment (Fig. 4) . No differences were found in the mean number and distribution of GnRH-ir cells in the POA and hypothalamus of control and ATR-treated animals (control, 84.6 6 28.1; ATR, 63.4 6 12.1; P ¼ 0.134, t(8) ¼ 0.69) (Fig.  4A) . Similarly, no difference was found in the overall amount of GnRH peptide in the hypothalami of ATR-treated animals (Fig. 4B) .
DISCUSSION
Previously, we have shown that high-dose ATR treatment resulted in decreased LH pulse frequency and increased amplitude without changing pituitary sensitivity to a GnRH receptor agonist [2] . Given the close association between GnRH and LH release, such data suggested that ATR decreases GnRH release. In the present study, we definitively show that ATR treatment results in reduced GnRH pulse frequency and increased amplitude. Previous studies have shown that ATR treatment reduces GnRH neuronal activation following a hormone-induced preovulatory surge and increases GnRH concentration at its primary site of release, the median eminence [3, 19] . This suggests that ATR works at the level of the hypothalamus to inhibit GnRH release.
To further understand the mechanism by which ATR inhibits GnRH activation and release, we used ISH to measure the level of GnRH mRNA of cells in the POA and hypothalamus of control animals and animals treated with relatively high doses of ATR (50, 100, or 200 mg/kg). No measurable differences were found in the number, distribution, or level of GnRH mRNA-expressing cells. Whereas the halflife of mature GnRH mRNA in vivo is thought to be rather short, the stores of GnRH transcript are large; therefore, small changes would be difficult to determine [20] . Due to the rapid processing of the primary transcript relative to mature mRNA, the assessments of hnRNA levels are a more direct reflection of rapid changes in gene transcription and could more accurately document changes in GnRH gene activation due to ATR [21, 22] . However, we detected no significant differences in the number of cells expressing GnRH hnRNA or in the expression level per cell. These data demonstrate that ATR does not interfere with the cellular expression of the GnRH mRNA and that reserves of GnRH transcript are available for pro-GnRH translation. These findings were not altogether surprising, because our previous data showed that 2 days after ATR withdrawal, animals experienced a significant increase in LH levels and GnRH activation, with full recovery by 4 days of withdrawal, suggesting that ATR was not functionally toxic to GnRH neurons [3] . Whereas posttranscriptional mechanisms have been implicated in the regulation of steady-state GnRH levels, immunohistochemistry and RIA data in the present study suggest no lack of available GnRH decapeptide but, rather, an inhibition of normal excitation and/or release in ATR-treated animals [23, 24] . However, the mechanism by which this inhibition occurs is unknown.
Both ATR and its metabolites are lipid soluble and able to cross the blood-brain barrier to directly affect GnRH neurons or upstream modulators [25] . Several neurotransmitters and neuropeptides involved in GnRH release have been reported to be altered by ATR. ATR can inhibit the binding of Ro15-4513 (a gamma-aminobutyric acid receptor antagonist) to cortical membranes [26] . In male and female rats, ATR has been reported to alter catecholamine content in the hypothalamus. ATR treatment has been shown to decrease the concentrations of norepinephrine in the anterior and medial basal hypothalamus but to increase or have no effect on dopamine levels in the hypothalamus [27] [28] [29] [30] . ATR has also been shown to have marginal competition (at micromolar levels) to the D and alpha 2 -adrenergic receptors [31] . It remains unclear if ATR works through one these upstream mediators of GnRH activity to effect pulsatile release or, perhaps, works directly on GnRH neurons.
Recently, it has been suggested that ATR may act on neuroendocrine activity by triggering adrenal hormone release. ATR treatment has been shown to increase progesterone and corticosterone (CORT) plasma concentrations in rodents [32] [33] [34] [35] . The possibility exists that activation of adrenal steroidogenesis could contribute to the observed alterations in LH release caused by ATR. The interaction between stress hormones and reproductive function has been known for many years (for reviews, see [36, 37] ). Although the mechanism by which the hypothalamic-pituitary-adrenal axis modifies the function of the hypothalamic-pituitary-gonadal (HPG) axis is not completely understood, stress hormones can act at all levels of the HPG axis [38] [39] [40] [41] [42] . High glucocorticoid levels cause decreased LH pulse frequency and increased amplitude [43] . Such changes in LH secretion are very similar to the findings of changes in GnRH/LH secretion following ATR treatment in the present and previous studies [2] . Notably, we have recently demonstrated that the presence of the adrenal gland is necessary for ATR to inhibit LH pulse secretion [34] . The most likely factors conferring this inhibition are CORT and/or progesterone. CORT and progesterone are secreted during times of adrenal activation and have been shown to be released after ATR treatment [33, 34] . Given this possibility, an important next step is to identify which hormonal component of adrenal secretion enables ATR to reduce LH pulse frequency. However, both of these hormones could very well be acting in conjunction to inhibit GnRH/LH release.
Because type II glucocorticoid receptor (GR; official symbol, NR3C1) and progesterone receptor (PR; official symbol, NR3C3) are not expressed in GnRH neurons [44, 45] , CORT and/or progesterone likely act indirectly to lower GnRH/LH pulsatile release. Strong evidence indicates that the primary inhibitory interneuronal system involved in regulating GnRH pulse frequency includes endogenous opioid peptides [46] [47] [48] . Administration of opioid peptides has been shown to inhibit LH pulse frequency [49] [50] [51] [52] . In particular, the endogenous opioid dynorphin is expressed in the arcuate nucleus and contains both GR and PR. Moreover, progesterone has also been shown to act upon dynorphin cells to increase dynorphin expression in this region, and immunoneutralization of dynorphin will block stress-induced inhibition of LH release [44, [53] [54] [55] [56] [57] .
Together, these findings suggest a scenario whereby high doses of ATR treatment may cause an increase in CORT and/or progesterone levels, leading to the activation of endogenous opioid neurons, most likely dynorphin, in the arcuate nucleus. The activation of the dynorphin neurons subsequently leads to the inhibition in GnRH pulsatility. Further work is needed to determine whether this neuronal group provides a substrate for interaction between CORT and progesterone and serves as a pathway by which ATR alters GnRH pulse frequency. Of particular interest is the presence of kisspeptin and neurokinin B neuropeptides in the same dynorphin neurons of the arcuate nucleus [58, 59] . The ''KNDy'' cells of the arcuate nucleus may be a mediator of ATR's effects on inhibition of GnRH release, delayed puberty, and precocious persistent estrus in the rat [8, [60] [61] [62] . Thus, the inhibition of LH pulses and the disruption of cyclicity in female rats treated with ATR likely is mediated by interference with central, fundamental mechanisms controlling GnRH release from the hypothalamus.
It remains unknown if the ATR induced reduction and modulation of GnRH/LH release results in disruption in reproductive fitness, but ATR, chlorotriazines, and chlorotriazine metabolites are found in soil, ground and drinking water, and foodstuffs [63] . The concentrations of these compounds are in the range of parts per billion. This would imply that the ATRAZINE'S EFFECTS ON GnRH EXPRESSION AND RELEASE levels of ATR in humans and wildlife species are well below the concentrations used in the present study. However, the present treatment paradigm of acute high-dose exposure may better model the application and corresponding environmental exposure to applicators and immediate runoff from application sites [64] [65] [66] .
In summary, high doses of ATR can act to inhibit hypothalamic GnRH release patterns in a fashion directly corresponding to those alterations seen in LH secretion. The GnRH secretory changes are not a consequence of changes in GnRH gene expression or protein levels and likely represent an effect on interneurons upstream of GnRH neurons. The identity of these neurons remains to be determined.
